Abstract-Genetic variants at SH2B3 are associated with blood pressure and circulating β 2 M (β-2 microglobulin), a wellcharacterized kidney filtration biomarker. We hypothesize that circulating β 2 M is an independent risk predictor of hypertension and may causally contribute to its development. The study sample consisted of 7 065 Framingham Heart Study participants with measurements of plasma β 2 M. Generalized estimating equations were used to test the association of β 2 M with prevalent and new-onset hypertension. There were 2 145 (30%) cases of prevalent hypertension at baseline and 886 (21%) cases of incident hypertension during 6 years of follow-up. A 1-SD increase in baseline plasma β 2 M was associated with a greater risk of prevalent (odds ratio 1.14, 95% CI 1.05-1.24) and new-onset (odds ratio 1.18, 95% CI 1.07-1.32) hypertension. Individuals within the top β 2 M quartile had a greater risk than the bottom quartile for prevalent (odds ratio 1.29, 95% CI 1.05−1.57) and new-onset (odds ratio 1.59, 95% CI 1.20-2.11) hypertension. These associations remained essentially unchanged in analyses restricted to participants free of albuminuria and chronic kidney disease. Mendelian randomization demonstrated that lower SH2B3 expression is causal for increased circulating β 2 M levels, and in a hypertensive mouse model, knockout of Sh2b3 increased β 2 M gene expression. In a community-based study of healthy individuals, higher plasma β 2 M levels are associated with increased risk of prevalent and incident hypertension independent of chronic kidney disease status. Overlapping genetic signals for hypertension and β 2 M, in conjunction with mouse knockout experiments, suggest that the SH2B3-β 2 M axis plays a causal role in hypertension. (Hypertension.
M (β-2-microglobulin), an essential component of the class I MHC (major histocompatibility complex), 1,2 is freely filtered in the glomerulus and reabsorbed in the proximal tubule, with circulating levels tightly maintained in healthy individuals. 3 A prior genome-wide association study of circulating β 2 M identified genetic variants at the MHC and SH2B3 genetic loci, 4 with one of the top single nucleotide polymorphisms for circulating β 2 M at the SH2B3 locus, rs3184504, also being a genome-wide significant single nucleotide polymorphisms for blood pressure (BP). 5 Therefore, given the concurrence of genetic variants for BP and circulating β 2 M, we hypothesized that β 2 M may be a causal factor for hypertension.
Hypertension is preventable through lifestyle interventions and drug treatment, 6, 7 but it still remains the most widespread noncommunicable disease worldwide. 8, 9 Previous population studies of β 2 M and hypertension are either limited to cross-sectional analyses 10 or did not consider kidney disease status. 11 To address these limitations, we sought to determine whether plasma β 2 M was associated with hypertension cross-sectionally and longitudinally and to assess its potential clinical utility as a prognostic indicator of hypertension risk. We also performed secondary analyses excluding individuals with albuminuria and low estimated glomerular filtration rate (eGFR) at baseline because elevated urinary β 2 M levels have been reported to be associated with impaired kidney function. 10 Lastly, we provide results of a functional study in Sh2b3-knockout mice to explore a causal role of the SH2B3-β 2 M axis in hypertension.
Materials and Methods
All source data and materials have been made publicly available at dbGaP (accession number phs000363.v17.p11). February 2019
Study Population
The cross-sectional study sample consisted of the Framingham Heart Study (FHS) Offspring and Third Generation cohort participants. [12] [13] [14] A total of 7 242 participants had measurements of plasma β 2 M 15 at the baseline examination (Offspring cohort examination 7 [1999-2003, n=3267] and Third Generation cohort examination 1 [2002-2005, n=3975] ). Participants with the following conditions were excluded: myocardial infarction or heart failure before baseline; missing information about use of antihypertensive treatment, lipid-lowering treatment, and diabetes mellitus medication use; and missing information on cigarette smoking, body-mass index, fasting glucose, total-density lipoprotein or HDL (high-density lipoprotein) cholesterol, triglycerides, or serum creatinine-leaving a final cross-sectional sample size of 7 065.
Participants who attended the follow-up examination (Offspring cohort examination 8 [2005-2008] and Third Generation cohort examination 2 [2008] [2009] [2010] [2011] ) ≈6 years after baseline (median 6.0, 25th and 75th percentiles 6.0, 7.0 years after baseline) and were normotensive at baseline made up the longitudinal study sample (n=4 189). Secondary longitudinal analyses were performed after excluding those with albuminuria (defined as urinary albumin-creatinine ratio ≥30 mg/g) or low eGFR (eGFR<60 mL/min per 1.73 m 2 ) at baseline.
Quantification of Plasma β 2 M Protein
Plasma β 2 M concentration was measured at baseline as part of the Systems Approach to Biomarker Research in Cardiovascular Disease Initiative. 16 A modified sandwich ELISA, multiplexed on a Luminex xMAP platform (Sigma-Aldrich) 17 was used, as described previously. 18 All targets were first developed as single assays, after which compatible targets, with appropriate plasma analyte concentration ranges, were combined to form multiplex panels to avoid cross-reactivity. For the β 2 M assay, the detection antibody was product number 200-406-141s (Rockland Antibodies, Limerick, PA), the capture antibody was GTX20759 (Genetex, Irvine, CA), and the reference protein was number 126-11 (Lee BioSolutions, Maryland Heights, MO). The mean intra-assay coefficient of variation for β 2 M was 3.7%.
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Data Collection for Covariates
Each the FHS examination consisted of an in-person interview, physician-administered physical examination, anthropometric measurements, BP measurements, and blood/urine sample collection. BMI was calculated as weight (kg) divided by the square of height (m 2 ). Current cigarette smoking was defined as self-reported smoking of at least 1 cigarette per day, on average, during the year preceding the examination. Information on antihypertensive and lipid-lowering medication use was collected via a self-administered questionnaire and verified using medications that participants brought to the research clinic visit. Diabetes mellitus was defined as fasting blood glucose ≥126 mg/dL, or the current use of insulin or hypoglycemic medication. Participant spot urine samples were used to measure urinary albumin and creatinine levels, from which the urinary albumincreatinine ratio was calculated. Albuminuria was defined as a urinary albumin-creatinine ratio equal to or >30 mg/g. 19 Serum creatinine levels, measured using the Roche Hitachi 911 reader, were quantified using the modified Jaffe method 20 with a modified picric acid buffer solution to minimize interference and weighted by populationspecific distributions of age and sex. 21 eGFR was calculated using the CKD-epi equation. 22, 23 CKD was defined as eGFR <60mL/min per 1.73 m 2 .
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BP Measurement
BP was measured at the baseline and follow-up examinations. Systolic and diastolic BP were each measured twice by a physician in the left arm after 5 minutes of rest in the seated position, and mean values were used. Hypertension was defined as systolic BP ≥140 mm Hg, diastolic BP ≥90 mm Hg, or current antihypertensive medication use. 25 
Statistical Analyses
Generalized estimating equations were used to account for familial correlations in testing the association of baseline β 2 M concentration with prevalent and new-onset hypertension. In the generalized estimating equations models, nuclear family members were considered as clusters of measurements. The logit link function was applied for the dichotomous response variable, hypertension. All analyses for prevalent hypertension were adjusted for the following baseline covariates: age, sex, study cohort, BMI, diabetes mellitus, cigarette smoking, levels of total-and HDL-cholesterol, statin-use, and eGFR. Analyses for new-onset hypertension were adjusted for the same baseline covariates, along with baseline systolic and diastolic BP. Secondary analyses were performed after excluding individuals with prevalent CKD or albuminuria.
Reclassification analyses were conducted by comparing the predictive abilities of regression models with and without plasma β 2 M for new-onset hypertension, and used the integrated discrimination improvement and net reclassification improvement metrics. 26, 27 Bootstrapping with 1 000 iterations was used for probability estimates, 26 and 2-sided P <0.05 were considered statistically significant. All analyses were conducted using SAS software version 9.4.
Mendelian Randomization
A 2-sample inverse-variance weighted Mendelian randomization (MR) approach was used to test whether SH2B3 expression was causal for plasma β 2 M levels. Pruned cis-eQTL variants (expression quantitative trait loci; LD r 2 <0.1) for SH2B3 expression 28 were used as instrumental variables for SH2B3 expression with SH2B3 expression as the exposure and circulating β 2 M levels as the outcome. SH2B3 expression was measured as described previously. 28 Briefly, fasting whole blood samples were collected from the FHS participants in PAXgene tubes (PreAnalytiX, Hombrechtikon, Switzerland) and stored at −80°C. Total RNA was isolated from frozen PAXgene tubes by Asuragen, Inc, and used to generate cDNA. The cDNA was fragmented and labeled using the FL-Ovation cDNA Biotin Module, after which the resultant cDNA fragments were allowed to hybridize overnight to the Affymetrix human exon 1.0 ST microarray platform according to the manufacturer's protocol (Affymetrix, Santa Clara, CA). The GeneChip 7G GCS3000 scanner (Thermo Fisher Scientific, Waltham, MA) was used to laser scan the microarray after washing and staining using the GeneChip Fluidics Station 450. Intensity values for each gene chip were compiled and normalized using the robust multichip average method from Affymetrix Power Tools Software version 1.12.0 (Affymetrix) before and after quality control.
All MR analyses were conducted using MRbase (http://www. mrbase.org/). Causal effect estimates of SH2B3 expression on plasma β 2 M levels are reported as effect per risk allele on inverse ranknormalized protein level. Because we lacked cis-pQTL variants for circulating β 2 M levels, we were unable to conduct MR analyses to determine if plasma β 2 M is causal for hypertension.
Mouse Models
Wild-type (WT) C57B1/6J mice were purchased from Jackson Laboratories (Bar Harbor, ME). Sh2b3-deficient C57BL/6J mice were generated by deleting exons 3 to 8 of Sh2b3, as described previously. 29, 30 Osmotic mini-pumps (model 2002, Alzet, DURECT Corporation, City, State) were implanted subcutaneously in mice ≈8 to 12 weeks of age for angiotensin II (490 ng/kg per min) or vehicle (sodium chloride/acetic acid solution) infusion for 14 days. RNA was extracted from whole blood of WT and Sh2b3 −/− mice using a RiboPure RNA purification Kit (Cat no. AM1928, Life Technologies, Carlsbad, CA), and cDNA was constructed using VANTAGE (Vanderbilt Technologies for Advanced Genomics, Vanderbilt University Medical Center, Nashville, TN). RNA sequencing reads first underwent quality control using the FASTX-Toolkit package (http://hannonlab.cshl.edu/fastx_toolkit/), after which they were mapped to the mouse reference genome (UCSC [University of California Santa Cruz] mm10) using Tophat v2.0. 31 mRNA levels were estimated and normalized using Cufflinks v2.2 and are reported in expected number of FPKM (fragments per kilobase of transcript sequence per million) base pairs sequenced. 32 Cuffdiff was used to identify differential expression of β 2 M between WT and SH2B3 −/− mice (http://cole-trapnell-lab.github.io/cufflinks/ cuffdiff/).
Results
Baseline Characteristics
Summary demographic and clinical characteristics of the study sample (mean age 49 years, 54% women) are shown in Table 1 according to β 2 M quartiles and Table S1 in the onlineonly Data Supplement for the overall study sample.
Cross-Sectional Analyses
Baseline β 2 M concentration was positively associated with prevalent hypertension after adjusting for clinical covariates with an odds ratio of 1.14 (95% CI 1.05-1.24, P=0.003) per SD increase in log-transformed β 2 M, and an odds ratio of 1.29 (95% CI 1.05-1.57, P=0.01) for the top versus bottom β 2 M quartile ( Table 2) .
Longitudinal Analyses
A total of 886 (21%) participants who were normotensive at baseline developed new-onset hypertension after a mean follow-up of 6 years. Results of the generalized estimating equations model revealed a significant association between baseline β 2 M and risk of new-onset hypertension with an odds ratio of 1.18 (95% CI 1.07-1.32, P=0.001) per SD increase in log-transformed β 2 M (Table 3) . Results of the quartile analysis showed that the top β 2 M quartile had a 1.59-fold risk (95% CI 1.20-2.11, P=0.001) of incident hypertension versus those in the bottom quartile (Table 3) . Excluding individuals with albuminuria and low eGFR at baseline did not materially change the results (Table S2) .
Reclassification Analyses
Reclassification metrics revealed that β 2 M improved the prediction of new-onset hypertension over the clinical model, which consisted of the following baseline covariates: age, sex, study cohort, BMI, diabetes mellitus, cigarette smoking, levels of total and HDL-cholesterol, statin-use, eGFR, and systolic and diastolic BP. Addition of β 2 M to the clinical model improved the discrimination for new-onset hypertension in the overall sample (integrated discrimination improvement, 0.0021; P=0.03) and in those free of baseline albuminuria and CKD (integrated discrimination improvement, 0.0036; P=0.008; Table 4 ). The continuous net reclassification index was statistically significant in participants free of baseline albuminuria and low eGFR (net Table 4 ).
Mendelian Randomization
As the top genetic variant (rs3184504) associated with plasma β 2 M levels is also associated with SH2B3 expression, 33 we postulated that the trans-effects (>1 megabase upstream or downstream of the transcription start site) of the rs3184504 polymorphism on β 2 M levels may be mediated through its cis-effects (within 1 megabase) on SH2B3 expression. To test this hypothesis, we conducted 2-sample inverse-variance weighted MR using all independent cis variants (LD r 2 <0.1) for SH2B3 expression as instrumental variables, SH2B3 expression as the exposure, and circulating β 2 M levels as the outcome. Decreased SH2B3 expression was found to be causal for higher β 2 M levels (β=−16.8, P=8.7E-11; Figure 1 ).
Sh2b3 −/− Mouse Model
To recapitulate the effects of cis genetic variation within SH2B3, we tested the effects of SH2B3 deficiency on β 2 M expression at baseline and in response to angiotensin II-induced hypertension. The rs3184504 polymorphism is associated with reduced SH2B3 function in humans, 35 and we previously reported that Sh2b3 −/− mice had a greater hypertensive response and more severe renal/vascular dysfunction in response to angiotensin II infusion. 34 Analysis of RNA sequencing performed on whole blood from wild-type and Sh2b3 −/− mice revealed a significant induction of β 2 M expression in response to angiotensin II administration only in Sh2b3 −/− mice (P=0.037; Figure 2 ) suggesting that SH2B3 normally constrains β 2 M expression in response to hypertensive stimuli and that enhanced β 2 M expression may be causally related to the exaggerated hypertensive response and end-organ damage seen in Sh2b3 −/− animals.
Discussion
Motivated by genome-wide association study variants at the SH2B3 locus that were reported to be associated both with BP 5 and circulating β 2 M levels, 4 we first explored the association of circulating β 2 M with prevalent and incident hypertension in a large community-based cohort study. We found that circulating β 2 M was associated with clinically relevant increases in prevalent and new-onset hypertension, replicating association results previously reported by investigators from the Atherosclerosis Risk in Communities study. 11 Secondary longitudinal association analyses between β 2 M and hypertension conducted in the FHS participants free of baseline CKD and albuminuria demonstrated similar effect sizes and consistent directions of effect compared with the overall study sample, thus suggesting β 2 M is more than a marker of renal dysfunction. Our MR analyses and mechanistic study in mice suggest that the SH2B3-β 2 M axis may play a causal role in BP regulation. Reclassification analyses, however, reveal that whereas the addition of β 2 M to a clinical model improved hypertension prediction, the magnitude of effect suggests that circulating β 2 M level is not likely to be a clinically useful biomarker of hypertension risk.
Hypertension is a complex disorder with a prominent renal component characterized by impaired renal sodium excretion, The clinical model for hypertension consisted of the following baseline covariates: age, sex, study cohort, BMI, diabetes mellitus, cigarette smoking, levels of total and HDL-cholesterol, statin-use, eGFR, and systolic and diastolic blood pressure. For the NRI, the case validation, or additional percentage of events correctly reclassified over clinical model, was 1% in the general sample and 3% in those free of baseline albuminuria and CKD; the noncase validation, or additional percentage of nonevents correctly reclassified over the clinical model, was 0% for the general sample and those free of baseline albuminuria and CKD. BMI indicates body mass index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; and HDL, high-density lipoprotein. *P<0.05. vascular remodeling, inflammation, and fibrosis. 36, 37 Genes within the HLA and SH2B3 regions have been implicated in inflammation, 38 and recent Sh2b3-knockout studies in mice have linked mutations or deletions in SH2B3 with kidney inflammation, 39 hypertension, 30, 40, 41 and atherosclerotic cardiovascular disease. 34, 35, 42, 43 Therefore, we sought to determine if there was a mechanistic link between SH2B3, β 2 M, and hypertension. To this end, we first conducted MR and found that lower SH2B3 expression increases circulating β 2 M levels ( Figure 1 ). Because of a lack of cis genetic variants for circulating β 2 M, we were unable to conduct MR to determine whether circulating β 2 M is causal for hypertension. We previously reported that Sh2b3 −/− mice develop an exaggerated BP response and more severe end-organ damage (renal and vascular inflammation and dysfunction) in response to angiotensin II. 30 We extend these findings in the present study by reporting that β 2 M expression is significantly increased in response to angiotensin II infusion in Sh2b3 −/− but not wild-type mice ( Figure 2 ). We thus provide evidence for a causal role of the SH2B3-β 2 M axis in hypertension.
To our knowledge, ours is the first study to demonstrate that SH2B3 might regulate hypertension not only via production of its coded protein, the LNK (lymphocyte adaptor protein), but also through effects on β 2 M expression. Deficiency of LNK increases interferon-γ producing CD8 + T-cells in the spleen and kidneys of hypertensive mice, and both interferon gamma and CD8 + T-cells are mediators of hypertension. 30,44 β 2 M is essential for MHC-I-mediated CD8 + T-cell activation. 45 Our finding that loss of LNK increases β 2 M expression under hypertensive conditions is consistent with our MR results. We hypothesize that loss of SH2B3 and a resultant increase in β 2 M levels likely leads to increased CD8 + T-cell activation and interferon-γ production, which promote hypertension and hypertensive end-organ damage (Figure 1) .
Our study has several strengths. First, the sample size was large and adequate to assess the relations of β 2 M to prevalent and incident hypertension. Second, BP and eGFR were meticulously ascertained, minimizing recall bias. Third, association results for prevalent and incident hypertension largely replicate those of an independent external study. 11 We acknowledge several study limitations. First, circulating β 2 M was only measured at the baseline examination, preventing analyses of temporal variation in plasma β 2 M. In addition, this was a European ancestry study sample; the extent to which our results are indicative of what would be observed in other racial/ethnic groups is unknown. Third, a substantial proportion of participants did not have measurement of urinary albumin, resulting in a smaller sample size for secondary longitudinal analyses that excluded those Figure 1 . Mendelian randomization demonstrating SH2B3 expression to be causal for plasma β 2 M levels and how both increase hypertension risk. Mendelian randomization (MR) analyses were conducted using rs3184504 to instrument SH2B3 expression to determine the causal effect of SH2B3 expression on circulating β 2 M levels. rs3184504(T) is a cis-eQTL variant for SH2B3 expression (β=−0.08, P=3.2E-06), trans-pQTL variant for circulating β 2 M (β=0.12, P=9.7E-11), and genome-wide association study (GWAS) single nucleotide polymorphisms (SNP) associated with systolic (β=0.58, P=5E-09) and diastolic (β=0.48, P=3E-14) blood pressure. 34 The MR Wald ratio demonstrated that SH2B3 expression was causal for circulating β 2 M (β=−16.8, P=8.7E-11). with CKD or albuminuria. Fourth, we applied an inclusive definition for hypertension that included elevated BP or antihypertensive medication use. Finally, we were unable to conduct MR of plasma β 2 M in relation to hypertension due to a lack of cis genetic variants for circulating β 2 M.
In summary, we have identified β 2 M to be cross-sectionally and longitudinally associated with hypertension risk independent of albuminuria and kidney disease and provide functional evidence of a causal role of the SH2B3-β 2 M axis in hypertension. Future studies are needed to further understand the mechanistic role of β 2 M in hypertension and determine if there is therapeutic efficacy in targeting the SH2B3-β 2 M axis for hypertension treatment or prevention.
Perspectives β 2 M is cross-sectionally and longitudinally associated with hypertension in the FHS participants with and without kidney dysfunction. Mendelian randomization analysis and studies using a murine model of hypertension provide evidence for a causal role of the SH2B3-β 2 M axis in blood pressure regulation. Future studies are needed to determine whether β 2 M is a clinically useful prognostic indicator of hypertension and whether there is therapeutic utility in targeting the SH2B3-β 2 M axis for hypertension prevention and treatment.
